New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented ...
UroToday55m
ASCO GU 2025: Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma (mRCC) in the US Community Setting.
American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Poster Session C: Renal Cell Cancer; ...